BRPI0907641A2 - Piridinas fundidas ativas como inibidores de c-met - Google Patents
Piridinas fundidas ativas como inibidores de c-metInfo
- Publication number
- BRPI0907641A2 BRPI0907641A2 BRPI0907641-7A BRPI0907641A BRPI0907641A2 BR PI0907641 A2 BRPI0907641 A2 BR PI0907641A2 BR PI0907641 A BRPI0907641 A BR PI0907641A BR PI0907641 A2 BRPI0907641 A2 BR PI0907641A2
- Authority
- BR
- Brazil
- Prior art keywords
- met inhibitors
- fused pyridines
- active fused
- active
- pyridines
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0801416.9A GB0801416D0 (en) | 2008-01-25 | 2008-01-25 | Pharmaceutical compounds |
| PCT/GB2009/000211 WO2009093049A1 (en) | 2008-01-25 | 2009-01-26 | Fused pyridines active as inhibitors of c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907641A2 true BRPI0907641A2 (pt) | 2015-07-21 |
Family
ID=39186355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907641-7A BRPI0907641A2 (pt) | 2008-01-25 | 2009-01-26 | Piridinas fundidas ativas como inibidores de c-met |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110053935A1 (pt) |
| EP (1) | EP2247584A1 (pt) |
| JP (1) | JP2011510058A (pt) |
| KR (1) | KR20100110344A (pt) |
| CN (1) | CN102015678A (pt) |
| AU (1) | AU2009207421A1 (pt) |
| BR (1) | BRPI0907641A2 (pt) |
| CA (1) | CA2712791A1 (pt) |
| GB (1) | GB0801416D0 (pt) |
| IL (1) | IL206930A0 (pt) |
| MX (1) | MX2010007714A (pt) |
| WO (1) | WO2009093049A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009303602B2 (en) | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| KR20110133048A (ko) | 2009-03-21 | 2011-12-09 | 닝 시 | 아미노 에스테르 유도체, 그의 염 및 이용 방법 |
| EP2332939A1 (en) * | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| KR101940340B1 (ko) * | 2011-03-04 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 아미노-퀴놀린 |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| DK2753329T3 (en) * | 2012-01-19 | 2017-10-23 | Onco Therapy Science Inc | 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
| CN103467374A (zh) * | 2013-08-30 | 2013-12-25 | 江苏弘和药物研发有限公司 | 一种8-溴-4-羧基喹啉的合成方法 |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| CN103694145B (zh) * | 2013-11-28 | 2016-02-10 | 山东鑫泉医药有限公司 | （2-甲基-5-硝基苯基）胍硫酸盐的合成方法 |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN105566313A (zh) * | 2016-03-22 | 2016-05-11 | 陕西思尔生物科技有限公司 | 头孢洛林酯中间体4-(4’-吡啶)-1,3-噻唑-2-硫醇的合成方法 |
| CN107573264A (zh) * | 2017-08-14 | 2018-01-12 | 贵州大学 | 一种3‑氰基‑5‑甲氧基苯‑1‑磺酰氯的制备工艺 |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CN112759536A (zh) * | 2019-11-05 | 2021-05-07 | 常州锐博生物科技有限公司 | 取代的苯磺酰氯的制备方法 |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| MXPA06012613A (es) * | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
| NZ564065A (en) * | 2005-05-20 | 2011-03-31 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| CL2007000995A1 (es) * | 2006-04-11 | 2008-06-27 | Smithkline Beecham Corp | Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras. |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
-
2008
- 2008-01-25 GB GBGB0801416.9A patent/GB0801416D0/en not_active Ceased
-
2009
- 2009-01-26 CA CA2712791A patent/CA2712791A1/en not_active Abandoned
- 2009-01-26 JP JP2010543574A patent/JP2011510058A/ja active Pending
- 2009-01-26 BR BRPI0907641-7A patent/BRPI0907641A2/pt not_active IP Right Cessation
- 2009-01-26 AU AU2009207421A patent/AU2009207421A1/en not_active Abandoned
- 2009-01-26 MX MX2010007714A patent/MX2010007714A/es not_active Application Discontinuation
- 2009-01-26 US US12/864,112 patent/US20110053935A1/en not_active Abandoned
- 2009-01-26 KR KR1020107016733A patent/KR20100110344A/ko not_active Withdrawn
- 2009-01-26 EP EP09704615A patent/EP2247584A1/en not_active Withdrawn
- 2009-01-26 CN CN2009801113771A patent/CN102015678A/zh active Pending
- 2009-01-26 WO PCT/GB2009/000211 patent/WO2009093049A1/en not_active Ceased
-
2010
- 2010-07-11 IL IL206930A patent/IL206930A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100110344A (ko) | 2010-10-12 |
| WO2009093049A1 (en) | 2009-07-30 |
| EP2247584A1 (en) | 2010-11-10 |
| MX2010007714A (es) | 2010-08-09 |
| US20110053935A1 (en) | 2011-03-03 |
| AU2009207421A1 (en) | 2009-07-30 |
| CA2712791A1 (en) | 2009-07-30 |
| CN102015678A (zh) | 2011-04-13 |
| IL206930A0 (en) | 2010-12-30 |
| GB0801416D0 (en) | 2008-03-05 |
| JP2011510058A (ja) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907641A2 (pt) | Piridinas fundidas ativas como inibidores de c-met | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| PT2528897E (pt) | Derivados de piridina dissubstituída como anticancerígenos | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| BR112012000763A2 (pt) | derivados de piridin-4-ila | |
| BRPI1013821A2 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
| EP2320221A4 (en) | ELECTRODE | |
| BRPI0922845A2 (pt) | pirazol-4-n-alcoxicarboxamidas como microbiocidas | |
| EP2346734A4 (en) | ACTIVE WINGLET | |
| BRPI0914895A2 (pt) | artigo absorvente | |
| BRPI0918372A2 (pt) | artigo absorvente | |
| BRPI0821175A2 (pt) | artigo absorvente | |
| BRPI0820241A2 (pt) | artigo absorvente | |
| BRPI0914657A2 (pt) | piridin-2-onae piridazin-3-onas substituídas | |
| BRPI0911444A2 (pt) | benzoimidazóis como inibidores de prolil hidroxilase | |
| ES2598358T8 (es) | Derivados de quinolina como inhibidores de PI3K quinasa | |
| BRPI0911347A2 (pt) | gama lactamas substituídas como agentes terapêuticos | |
| BR112013015449A2 (pt) | compostos de bi-heteroarila como inibidores de vps23 | |
| CR20130403A (es) | Derivados de fluoro-piridinona útiles como agentes antibacterianos | |
| DK2246017T3 (da) | Absorberende genstand | |
| BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases | |
| BRPI0912475A2 (pt) | compostos como inibidores de quinase | |
| BRPI1014077A2 (pt) | Derivados de tiazolilperidina como fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |